NCT06736509 - An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study | Biotech Hunter

Enrollment

139

Participants

Timeline

Start Date

November 21, 2024

Primary Completion Date

February 17, 2025

Study Completion Date

April 25, 2025

Conditions

Agitation in Patients With Dementia of the Alzheimer's TypeAlzheimer DiseaseAgitation, Psychomotor

Interventions

DRUG

AXS-05 (dextromethorphan-bupropion)

AXS-05 tablets, taken twice daily

Trial Locations (22)

11229

Clinical Research Site, Brooklyn

22205

Clinical Research Site, Arlington

28211

Clinical Research Site, Charlotte

33012

Clinical Research Site, Hialeah

33014

Clinical Research Site, Miami Gardens

Clinical Research Site, Miami Lakes

33025

Clinical Research Site, Pembroke Pines

33126

Clinical Research Site, Miami

33145

Clinical Research Site, Miami

33155

Clinical Research Site, Miami

33165

Clinical Research Site, Miami

33173

Clinical Research Site, Miami

33467

Clinical Research Site, Green Acres

33511

Clinical Research Site, Brandon

33614

Clinical Research Site, Tampa

33634

Clinical Research Site, Tampa

34134

Clinical Research Site, Bonita Springs

75149

Clinical Research Site, Mesquite

85381

Clinical Research Site, Peoria

94596

Clinical Research Site, Walnut Creek

02184

Clinical Research Site, Braintree

00918

Clinical Research Site, San Juan